Latest Production News

The week was split between big earnings reactions and small-cap rocks-and-rigs rallies. Pro Medicus sank despite record numbers, while a handful of explorers jumped on fresh discoveries and policy wins.

Explorers led the Materials tape as fresh drill stories and new ground deals pulled buyers into small caps. Big miners still delivered, but the loudest moves came from companies offering investors a near-term catalyst.

Takeover chatter lit up Pepper Money, while Identitii ran hard after a regulator stepped in. At the other end, AMP slid despite higher profit, as investors weighed leadership change and legal costs.

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Big moves came from disclosure drama, CEO change news, and one standout software upgrade. While several stocks jumped on results, a few gaps couldn’t hold as traders sold into early strength.

Neometals Ltd has resolved a longstanding legal dispute with a $1 million settlement, clearing the way to focus on advancing its Barrambie Gold Project and sustainable processing technologies.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

Sky Metals Limited has raised $20.5 million through a share placement to accelerate development of its flagship Tallebung Tin Project in NSW, positioning the company for near-term tin production.

BrainChip has launched its AKD2500 silicon development project, advancing its Akida™ 2.0 neuromorphic AI platform with a $2.5 million investment and prototype expected by Q3 2026.

Felix Gold Limited has confirmed significant extensions to gold mineralisation at its NW Array prospect in Alaska's Treasure Creek, with high-grade assay results and broad gold halos around antimony veins. The mineralised system remains open for further expansion, supporting the company's dual-commodity strategy.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.